BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19543053)

  • 1. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.
    Cheng X; Dai H; Wan N; Moore Y; Vankayalapati R; Dai Z
    Transplantation; 2009 Jun; 87(12):1778-86. PubMed ID: 19543053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells.
    Nasr IW; Wang Y; Gao G; Deng S; Diggs L; Rothstein DM; Tellides G; Lakkis FG; Dai Z
    J Immunol; 2005 May; 174(10):6161-8. PubMed ID: 15879112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
    Gao W; Demirci G; Strom TB; Li XC
    Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection.
    Li T; Ma R; Zhu J; Wang F; Huang L; Leng X
    Chin Med J (Engl); 2014; 127(14):2686-92. PubMed ID: 25043090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.
    Koga N; Suzuki J; Kosuge H; Haraguchi G; Onai Y; Futamatsu H; Maejima Y; Gotoh R; Saiki H; Tsushima F; Azuma M; Isobe M
    Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2057-62. PubMed ID: 15374847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
    Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
    Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts.
    Takeda Y; Gotoh M; Dono K; Nishihara M; Grochowiecki T; Kimura F; Yoshida T; Ohta Y; Ota H; Ohzato H; Umeshita K; Takeda T; Matsuura N; Sakon M; Kayagaki N; Yagita H; Okumura K; Miyasaka M; Monden M
    Diabetologia; 1998 Mar; 41(3):315-21. PubMed ID: 9541172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
    Wang L; Han R; Hancock WW
    Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired recall of CD8 memory T cells in immunologically privileged tissue.
    Dai Z; Nasr IW; Reel M; Deng S; Diggs L; Larsen CP; Rothstein DM; Lakkis FG
    J Immunol; 2005 Feb; 174(3):1165-70. PubMed ID: 15661869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes.
    Wen X; Zhu H; Li L; Li Y; Wang M; Liu J; Yang D; Liao W; Shen G
    Transplantation; 2008 Dec; 86(11):1596-602. PubMed ID: 19077895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
    Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.
    Terrazas LI; Montero D; Terrazas CA; Reyes JL; Rodríguez-Sosa M
    Int J Parasitol; 2005 Nov; 35(13):1349-58. PubMed ID: 16126211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model.
    Mai G; del Rio ML; Tian J; Ramirez P; Buhler L; Rodriguez-Barbosa JI
    Xenotransplantation; 2007 May; 14(3):243-8. PubMed ID: 17489865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
    Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
    Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice.
    Ma D; Duan W; Li Y; Wang Z; Li S; Gong N; Chen G; Chen Z; Wan C; Yang J
    PLoS One; 2016; 11(3):e0152087. PubMed ID: 26990974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
    Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
    J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.
    Zhang C; Wu S; Xue X; Li M; Qin X; Li W; Han W; Zhang Y
    Cytotherapy; 2008; 10(7):711-9. PubMed ID: 18841514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.